HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)

THE LANCET ONCOLOGY (TLO)

Chernobyl, ionising radiation exposure, and cancer risk
The first review in this months TLO reviews the epidemiological evidence linking cancer incidence as a result of the 1986 Chernobyl nuclear explosion in the Ukraine. Most studies have focused on malignant diseases in children, specifically thyroid cancer and leukaemia. Authors of the review argue that there is good evidence to suggest that rates of thyroid cancer in children from the countries that were formally part of the Soviet Union have risen as a consequence of the Chernobyl accident. The findings for childhood leukaemia, they comment, are less conclusive. Among adult populations, there is no strong evidence to suggest that risk of thyroid cancer, leukaemia, or other malignant disease has increased as a result of the Chernobyl accident.

Hormone-replacement therapy (HRT) and breast cancer
HRT has been available for many years, but the important question of its place in development and progression of breast cancer remains controversial. This review summarises current clinical data, which suggest that short-term HRT use does not increase breast-cancer risk, although a small increase in risk is associated with long-term (more than 10 years) HRT use. The review highlights the need for prospective controlled trials in healthy women as well as those at higher risk of breast cancer or with a personal history of the disease.

A case for geriatric oncology
The increase in cancer incidence with increasing age is becoming more obvious and more important as the average age of the population increases. This review assesses the biological and clinical interactions of cancer and ageing and discusses the skills and knowledge necessary for caring for older patients.

A culture of mistrust
This months Leading Edge editorial examines the issues surrounding diet and cancer, especially media reports that often
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
1-May-2002


Page: 1 2 3

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO and The Lancet Infectious Diseases TLID

(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... only about half as likely as white women to become ... and the racial disparity persists even when donor eggs are ... patients became pregnant after IVF, compared to about 17 percent ... over two years to tease out the impact of race, ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
Cached News: